PPAR : a dagger in the heart of the metabolic syndrome
Open accessThe DOI matches its Crossref record; 97 of the 100 references it cites were found in a registry or an index.
Abstract
Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose tissue and muscle, and it suppresses macrophage-derived inflammation. Its combined activities in these and other tissues make it a multifaceted therapeutic target for the metabolic syndrome with the potential to control weight gain, enhance physical endurance, improve insulin sensitivity, and ameliorate atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both overexpression and activation of PPARδ result in increased mitochondrial biogenesis in the absence of an increase in PGC-1α mRNA in skeletal muscle in vivo (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The finding that overexpression of PPARδ in skeletal muscle of transgenic mice does not result in an increase in PGC-1α mRNA led to the conclusion that the increase in mitochondria is mediated directly by PPARδ (17–19).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to the finding in mouse and rat skeletal muscle that PPARδ overexpression or activation does not result in an increase in PGC-1α mRNA, a number of studies have shown that PPARδ induces an increase in PGC-1α gene transcription, with a rapid increase in PGC-1α mRNA, in myotubes (19, 50, 51).”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The regulation of PGC-1α expression by PPARδ differs markedly between skeletal muscle in vivo and myotubes in culture.”
From High-fat diets cause insulin resistance despite an increase in muscle mitochondria (2008) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Research works printed but not linked: 1
- [77]Lee, C.H., et al. 2006. PPAR delta is a potent insulin sensitizer. Proc. Natl. Acad. Sci. U. S. A. In press.
Cited by
Items 201–300 of 738
Nogueira, L. M., Lavigne, J. A., Chandramouli, G. V. R., Lui, H., Barrett, J. C., & Hursting, S. D. (2012) · Cancer Medicine · doi:10.1002/cam4.23 · Cited by 56
Goto, T., Kim, Y., Takahashi, N., & Kawada, T. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200522 · Cited by 59
Quang, T. H., Ngân, N. T. T., Minh, C. V., Kiệm, P. V., Tài, B. H., Thảo, N. P., Song, S. B., & Kim, Y. H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.136 · Cited by 59
Meibomian Gland Dysfunction: What Have Animal Models Taught Us?
Sun, M., Moreno, I. Y., Dang, M., & Coulson‐Thomas, V. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228822 · Cited by 60
“Among the three PPAR families, PPARγ is most highly expressed in white adipose tissue (WAT) and brown adipose tissue (BAT), where it is a master regulator of adipogenesis, as well as a potent modulator of whole-body lipid metabolism and insulin sensitivity [62,64].”
BackgroundPPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?
Balakumar, P., Rose, M., & Singh, M. (2007) · Pharmacology · doi:10.1159/000102594 · Cited by 59
Ashmore, T., Roberts, L. D., Morash, A. J., Kotwica, A. O., Finnerty, J., West, J. A., Murfitt, S. A., Fernandez, B. O., Branco, C., Cowburn, A. S., et al. (2015) · BMC Biology · doi:10.1186/s12915-015-0221-6 · Cited by 52
Shen, J., Yang, T., Xu, Y., Luo, Y., Zhong, X., Shi, L., Hu, T., Guo, T., Nie, Y., Luo, F., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103022 · Cited by 58
Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57
Corzo, C. A., & Griffin, P. R. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.395 · Cited by 57
Bojic, L. A., Burke, A. C., Chhoker, S. S., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Tirona, R. G., Yin, H., Pickering, J. G., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301830 · Cited by 52
Goto, T., Kim, Y.-I., Funakoshi, K., Teraminami, A., Uemura, T., Hirai, S., Lee, J.-Y., Makishima, M., Nakata, R., Inoue, H., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00061.2011 · Cited by 57
Pokrywka, A., Kaliszewski, P., Majorczyk, E., & Zembroń-Łacny, A. (2013) · Biology of Sport · doi:10.5604/20831862.1059606 · Cited by 58
Ren, X., Kuo, Y., & Blumberg, B. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110926 · Cited by 56
“PPARδ is ubiquitously expressed and can also promote fatty acid oxidation (Barish et al., 2006).”
BackgroundLigand Specificity of Nuclear Hormone Receptors: Sifting through Promiscuity
Noy, N. (2007) · Biochemistry · doi:10.1021/bi7018699 · Cited by 55
New Insights into the PPARγAgonists for the Treatment of Diabetic Nephropathy
Jia, Z., Sun, Y., Yang, G., Zhang, A., Huang, S., Heiney, K. M., & Zhang, Y. (2014) · PPAR Research · doi:10.1155/2014/818530 · Cited by 55
Emerging roles of PPARδ in metabolism
Seedorf, U., & Aberle, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.017 · Cited by 55
Vignati, S., Albertini, V., Rinaldi, A., Kwee, I., Riva, C., Oldrini, R., Capella, C., Bertoni, F., Carbone, G. M., & Catapano, C. V. (2006) · Neoplasia · doi:10.1593/neo.06433 · Cited by 55
Naples, S. P., Borengasser, S. J., Rector, R. S., Uptergrove, G. M., Morris, E. M., Mikus, C. R., Koch, L. G., Britton, S. L., Ibdah, J. A., & Thyfault, J. P. (2010) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h09-139 · Cited by 54
“PPARδ is believed to provide a coordinated response to high fat feeding that will increase the disposal of fatty acids (Muoio et al. 2002; Barish et al. 2006).”
BackgroundThe role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
Huang, T. H.-W., Teoh, A. W., Beilun, L., Lin, D. S.-H., & Roufogalis, B. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.020 · Cited by 54
Sakamoto, T., & Kelly, D. P. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.12.008 · Cited by 53
Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.010 · Cited by 53
PPARγ Regulation in Hypertension and Metabolic Syndrome
Stump, M., Mukohda, M., Hu, C., & Sigmund, C. D. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0601-x · Cited by 48
Docosahexaenoic acid suppresses the expression of FoxO and its target genes
Chen, Y.-J., Chen, C.-C., Li, T., Wang, P.-H., Liu, L.-R., Chang, F.-Y., Wang, Y.-C., Yu, Y., Lin, S., Mersmann, H. J., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.003 · Cited by 52
Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 52
“While PPARγ isoform is mainly expressed in white and brown adipose tissue, the large intestine and spleen, in which it regulates adipogenesis, energy balance, lipid biosynthesis and inflammation [154], PPARβ/δ is expressed ubiquitously in all tissues and is the most abundant isoform found in liver, kidney, adipose tis…”
BackgroundGrasselli, E., Voci, A., Canesi, L., Goglia, F., Ravera, S., Panfoli, I., Gallo, G., & Vergani, L. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0074 · Cited by 50
Mölzer, C., Wallner, M., Kern, C., Tosevska, A., Schwarz, U., Zadnikar, R., Doberer, D., Marculescu, R., & Wagner, K. (2016) · Scientific Reports · doi:10.1038/srep30051 · Cited by 52
Peroxisome Proliferator-Activated Receptor-α Activation Inhibits Langerhans Cell Function
Dubrac, S., Stoitzner, P., Pirkebner, D., Elentner, A., Schoonjans, K., Auwerx, J., Saeland, S., Hengster, P., Fritsch, P., Romani, N., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4362 · Cited by 47
“Although activation of PPAR and was clearly anti-inflammatory in monocytic cells and in atherosclerotic plaques (5, 12), activation of PPAR has yielded mixed results (12, 13).”
ResultNuclear receptors in regenerating liver and hepatocellular carcinoma
Vacca, M., Degirolamo, C., Massafra, V., Polimeno, L., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.025 · Cited by 51
Hussein, O. E., Hozayen, W. G., Bin-Jumah, M. N., Germoush, M. O., El-Twab, S. M. A., & Mahmoud, A. M. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-08557-y · Cited by 51
Reverse crosstalk of TGFβ and PPARβ/δ signaling identified by transcriptional profiling
Stockert, J., Adhikary, T., Kaddatz, K., Finkernagel, F., Meißner, W., Müller‐Brüsselbach, S., & Müller, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq773 · Cited by 51
Yang, Y., Tong, Y., Gong, M., Lu, Y., Wang, C., Zhou, M., Qiu, Y., Mao, T., & Tong, N. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.019 · Cited by 50
Koutroulis, I., Batabyal, R., McNamara, B., Ledda, M., Hoptay, C. E., & Freishtat, R. J. (2019) · Critical Care Explorations · doi:10.1097/cce.0000000000000061 · Cited by 50
New Therapeutic Target for Metabolic Syndrome: PPAR.DELTA.
Takahashi, S., Tanaka, T., & Sakai, J. (2007) · Endocrine Journal · doi:10.1507/endocrj.kr-99 · Cited by 50
“PPAR-RXR heterodimers bind to DNA specific sequences called PPAR responsive elements (PPREs) and regulate gene expression programs of fatty acid uptake and oxidation, lipid metabolism and inflammation [1-3].”
BackgroundPiantadosi, C. A., & Suliman, H. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709741200 · Cited by 50
Liu, S., Kam, W. R., Ding, J., Hatton, M. P., & Sullivan, D. A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11221 · Cited by 50
Kim, J., Kim, J., Yi, S., Shin, K.-H., Shin, H.-S., Yoon, S. H., Cho, J., Kim, D.-H., Shin, S., Jang, I., et al. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.023 · Cited by 50
Nutraceuticals and regulation of adipocyte life: Premises or promises
Colitti, M., & Grasso, S. (2014) · BioFactors · doi:10.1002/biof.1164 · Cited by 49
Yasuno, T., Osafune, K., Sakurai, H., Asaka, I., Tanaka, A., Yamaguchi, S., Yamada, K., Hitomi, H., Arai, S., Kurose, Y., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.084 · Cited by 49
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48
“PPARβ/δ regulates glucose utilization and lipoprotein metabolism by promoting reverse cholesterol transport [57–60].”
BackgroundTargeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 48
The elusive endogenous adipogenic PPARγ agonists: Lining up the suspects
Hallenborg, P., Petersen, R. K., Kouskoumvekaki, I. A., Newman, J. W. I., Madsen, L., & Kristiansen, K. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.11.002 · Cited by 48
Novel Pharmacotherapy Options for NASH
Ratziu, V. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4128-z · Cited by 49
Zaveri, N. T., Sato, B., Jiang, F., Calaoagan, J. M., Laderoute, K. R., & Murphy, B. J. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.13.8691 · Cited by 48
Benetti, E., Mastrocola, R., Rogazzo, M., Chiazza, F., Aragno, M., Fantozzi, R., Collino, M., & Minetto, M. A. (2013) · Mediators of Inflammation · doi:10.1155/2013/509502 · Cited by 43
Peroxisome proliferator-activated receptors as therapeutic targets for heart failure
Abushouk, A. I., Husseny, M. W. A. E., Bahbah, E. I., Elmaraezy, A., Ali, A. A., Ashraf, A., & Abdel‐Daim, M. M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.083 · Cited by 47
Umasuthan, N., Xue, X., Caballero‐Solares, A., Kumar, S., Westcott, J. D., Chen, Z., Fast, M. D., Škugor, S., Nowak, B. F., Taylor, R. G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072417 · Cited by 47
PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders
Djouadi, F., & Bastin, J. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0844-7 · Cited by 47
“Since then, the role of PPARd in the control of muscle mitochondrial b-oxidation has been confirmed, and is generally recognized (Barish et al 2006).”
BackgroundFritah, A., Steel, J. H., Nichol, D., Parker, N., Williams, S., Price, A. N., Strauss, L., Ryder, T. A., Mobberley, M. A., POUTANEN, M. H., et al. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvp418 · Cited by 47
PPARδ in humans: genetic and pharmacological evidence for a significant metabolic function
Karpe, F., & Ehrenborg, E. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd4b1 · Cited by 47
Sarov‐Blat, L., Kiss, R. S., Haidar, B., Kavaslar, N., Jaye, M., Bertiaux, M., Steplewski, K. M., Hurle, M. R., Sprecher, D. L., McPherson, R., et al. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.106.138990 · Cited by 47
Mettu, N. B., Stanley, T. B., Dwyer, M. A., Jansen, M. S., Allen, J. E., Hall, J. M., & McDonnell, D. P. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0201 · Cited by 44
Grarup, N., Albrechtsen, A., Ek, J., Borch‐Johnsen, K., Jørgensen, T., Schmitz, O., Hansen, T. F., & Pedersen, O. B. (2007) · Diabetologia · doi:10.1007/s00125-007-0668-2 · Cited by 46
“In recent years PPARδ has emerged as a key protein in the regulation of energy metabolism by its ability to enhance fatty acid catabolism, energy uncoupling and insulin sensitivity in the liver, adipose tissue and skeletal muscle [6–10, 36].”
BackgroundSan‐Millán, J. L., & Escobar-Morreale, H. F. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03679.x · Cited by 46
Han, J.-K., Kim, H.-L., Jeon, K.-H., Choi, Y.-E., Lee, H.-S., Kwon, Y.-W., Jang, J.-J., Cho, H.-J., Kang, H.-J., Oh, B.-H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehr365 · Cited by 43
Pan, D., Wang, W., Liu, N., Yang, Q., Zhang, K., Zhu, J.-Z., Shan, S., Li, Z., Ning, Z., Huang, L., et al. (2017) · PPAR Research · doi:10.1155/2017/4313561 · Cited by 47
Ray, D. M., Spinelli, S. L., Brien, J. J. O., Blumberg, N., & Phipps, R. P. (2006) · BioDrugs · doi:10.2165/00063030-200620040-00004 · Cited by 46
“[11-17] PPARδ/β is poorly understood but has been implicated in control- Soon after the identification of PPARs, it was determined that ling dyslipidemia, possibly contributing to the prevention of ather- the thiazolidinedione (TZD) class of anti-diabetic drugs were ogenesis.[5] A summary of the PPAR subtypes is shown…”
BackgroundConnor, E. E., Baldwin, R. L., Walker, M. P., Ellis, S. E., Li, C., Kahl, S., Chung, H., & Li, R. W. (2014) · Journal of Dairy Science · doi:10.3168/jds.2013-7471 · Cited by 45
Ringseis, R., Rosenbaum, S., Geßner, D. K., Herges, L., Kubens, J. F., Mooren, F., Krüger, K., & Eder, K. (2012) · Journal of Nutrition · doi:10.3945/jn.112.164038 · Cited by 45
Wang, D. Q. ‐., Portincasa, P., & Neuschwander‐Tetri, B. A. (2013) · Comprehensive physiology · doi:10.1002/cphy.c130001 · Cited by 44
Vascular effects of prostacyclin: does activation of PPARδ play a role?
Katušić, Z. S., Santhanam, A. V. R., & He, T. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.05.005 · Cited by 44
Xu, Y., Kume, S., Tanaka, Y., Isshiki, K., Araki, S., Chin‒Kanasaki, M., Sugimoto, T., Koya, D., Haneda, M., Sugaya, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025271 · Cited by 43
Immunomodulatory effects of eicosapentaenoic acid through induction of regulatory T cells
Iwami, D., Nonomura, K., Shirasugi, N., & Niimi, M. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.035 · Cited by 43
Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies
Heald, M., & Cawthorne, M. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_2 · Cited by 43
“However, the studies to date on PPAR-d suggest that it could be a good target to go alongside PPAR-g in the treatment of T2DM, which is almost exclusively an obese population (Barish et al. 2006; Lee et al. 2006).”
BackgroundBlock of Nuclear Receptor Ubiquitination
Genini, D., & Catapano, C. V. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609149200 · Cited by 43
Toyoda, T., Kamei, Y., Kato, H., Sugita, S., Takeya, M., Suganami, T., & Ogawa, Y. (2008) · Obesity · doi:10.1038/oby.2008.62 · Cited by 43
Harnessing the potential clinical use of medicinal plants as anti-diabetic agents
Campbell-Tofte, J., Mølgaard, & Winther (2012) · Botanics Targets and Therapy · doi:10.2147/btat.s17302 · Cited by 43
“Stimulation of PPARα increases the synthesis of healthy high-density lipoprotein cholesterol (HDL-C), PPARγ plays a critical role in promoting lipid storage,(50) while PPARδ suppresses macrophage-derived inflammation, enhances fatty acid catabolism, and energy uncoupling in adipose tissue and muscle.(51) These propert…”
BackgroundBae, J., Kumazoe, M., Fujimura, Y., & Tachibana, H. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.014 · Cited by 42
Lipid Metabolism and Renal Disease
Abrass, C. K. (2006) · Contributions to Nephrology · doi:10.1159/000095323 · Cited by 42
Increase of myocardial performance by Rhodiola–ethanol extract in diabetic rats
Cheng, Y., Chen, L., Lee, W., Chen, M.-F., Lin, H.-J., & Cheng, J. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.08.029 · Cited by 41
Liu, F., Shi, K., Dong, J., Jin, Z., Wu, Y., Cai, Y., Lin, T., Cai, Q., Liu, L., & Zhang, Y. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01256-9 · Cited by 41
Yang, Q., Chen, C., Wu, S., Zhang, Y., Mao, X., & Wang, W. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.025 · Cited by 41
Wyrwoll, C. S., Mark, P. J., Mori, T. A., & Waddell, B. J. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0210 · Cited by 34
Bastin, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.012 · Cited by 40
Perdoncin, M., Konrad, A., Wyner, J. R., Lohana, S., Pillai, S. S., Pereira, D. G., Lakhani, H. V., & Sodhi, K. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.756499 · Cited by 40
Hydroxy Monounsaturated Fatty Acids as Agonists for Peroxisome Proliferator-Activated Receptors
Yokoi, H., Mizukami, H., Nagatsu, A., Tanabe, H., & Inoue, M. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.854 · Cited by 40
Jang, J. C., & Nair, M. G. (2014) · Current Immunology Reviews · doi:10.2174/1573395509666131210232548 · Cited by 40
Hall, J. M., & McDonnell, D. P. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0060 · Cited by 38
Choi, K. C., Lee, S. Y., Yoo, H. J., Ryu, O., Lee, K. W., Kim, S. M., Baik, S. H., & Choi, K. M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.114 · Cited by 40
de Lange, P., Feola, A., Ragni, M., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., Amat, R., Villarroya, F., Goglia, F., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0206 · Cited by 40
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 39
“PPARd is expressed in skeletal and cardiac muscle, and adipose tissue, where it stimulates fat oxidation, and in liver and immune cells where it has roles in reducing hepatic glucose production and inflammation, respectively [44].”
BackgroundTranscriptomic evaluation of bovine blastocysts obtained from peri-pubertal oocyte donors
Morin-Doré, L., Blondin, P., Vigneault, C., Grand, F., Labrecque, R., & Sirard, M. (2017) · Theriogenology · doi:10.1016/j.theriogenology.2017.01.005 · Cited by 39
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0654-6 · Cited by 39
“Recent studies suggest that PPARβ/δ may be employed to treat metabolic syndrome, type2 diabetes, dyslipidemia, insulin resistance and vascular inflammation, though none of their modulators are of any clinical importance (Luquet et al. 2005; Barish et al. 2006).”
BackgroundTelle‐Hansen, V. H., Halvorsen, B. L., Dalen, K. T., Narverud, I., Wesseltoft-Rao, N., Granlund, L., Ulven, S. M., & Holven, K. B. (2013) · Genes & Nutrition · doi:10.1007/s12263-012-0329-z · Cited by 39
Nuclear Receptors Reverse McGarry's Vicious Cycle to Insulin Resistance
Moore, D. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.016 · Cited by 39
“PPARs (Barish et al., 2006; Lalloyer and Staels, 2010; Lehrke and Lazar, 2005), ERa (Bryzgalova et al., 2008b; Mauvais-Jarvis, 2011), CAR (Dong et al., 2009; Lahtela et al., 1985; Sotaniemi and Karvonen, 1989), FXR (Cipriani et al., 2010; Sanyal et al., 2009;Watanabe et al., 2006; Zhang et al.,…”
Induction of Metastatic Gastric Cancer by Peroxisome Proliferator-Activated Receptorδ Activation
Pollock, C. B., Rodriguez, O., Martin, P. L., Albanese, C., Li, X., Kopelovich, L., & Glazer, R. I. (2010) · PPAR Research · doi:10.1155/2010/571783 · Cited by 40
“PPARs are ligand-dependent nuclear receptors that regulate expression of a multiplicity of genes associated with metabolic disorders, such as type II diabetes and lipodystrophies [7, 8].”
BackgroundColl, T., Barroso, E., Álvarez-Guardia, D., Serrano, L., Salvadó, L., Merlos, M., Palomer, X., & Vázquez‐Carrera, M. (2010) · PPAR Research · doi:10.1155/2010/368467 · Cited by 38
“Activation of PPARβ/δ by its ligands (including GW501516) enhances fatty acid catabolism in adipose tissue and skeletal muscle, thereby delaying weight gain (for a review, see [72]).”
BackgroundInfluentialIlan, Y. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13833 · Cited by 38
Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
Ellis, H. P., & Kurian, K. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00052 · Cited by 37
PPARγ in Ischemia-Reperfusion Injury: Overview of the Biology and Therapy
Huang, R., Zhang, C., Wang, X., & Hu, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.600618 · Cited by 37
“The mechanism may be related to the suppression of proliferation as well as induction of differentiation and apoptosis (Evans et al., 2004; Barish et al., 2006).”
BackgroundEffects of Two Different Rhodiola rosea Extracts on Primary Human Visceral Adipocytes
Pomari, E., Stefanon, B., & Colitti, M. (2015) · Molecules · doi:10.3390/molecules20058409 · Cited by 37
Genetic links between diabetes mellitus and coronary atherosclerosis
Ordovás, J. M. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0020-9 · Cited by 37
Chen, W., Wang, L., Liu, H., Long, L., & Li, S. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00268.x · Cited by 37
Zhou, C., Zhou, J., Han, N., Liu, Z., Xiao, B., & Yin, J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.01.027 · Cited by 37
Regulation of Lymphocyte Function by PPAR γ : Relevance to Thyroid Eye Disease‐Related Inflammation
Lehmann, G. M., García-Bates, T. M., Smith, T. J., Feldon, S. E., & Phipps, R. P. (2008) · PPAR Research · doi:10.1155/2008/895901 · Cited by 37
“[159] G.”
BackgroundClinical Use of the Metabolic Syndrome: Why the Confusion?
Blaha, M. J., & Elasy, T. A. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.3.125 · Cited by 37
Ravaux, L., Denoyelle, C., Monne, C., Limon, I., Raymondjean, M., & Hadri, K. E. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00623-07 · Cited by 37
Jiang, W., Xu, S., Guo, H., Lu, L., Liu, J., Wang, G., & Hao, K. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15230 · Cited by 36
Tobita, Y., Arima, T., Nakano, Y., Uchiyama, M., Shimizu, A., & Takahashi, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155296 · Cited by 36
Adverse Intrauterine Environment and Cardiac miRNA Expression
Lock, M. C., Botting, K. J., Tellam, R. L., Brooks, D. A., & Morrison, J. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122628 · Cited by 36
“PPARδ p ays major role in the on et of cardiac failur [82] and is a t rget of miR-214.”
BackgroundPPARδ Is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells
Al‐Yacoub, N., Romanowska, M., Krauß, S., Schweiger, S., & Foerster, J. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.32 · Cited by 36
Metadata
- Authors
- Barish, G. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Corresponding author
- Barish, G. D.
- ORCID
- Barish, G. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-03-01
- Volume
- 116
- Issue
- 3
- Pages
- 590-597
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1386117
- OpenAlex
- W1987601141
- Cited by
- 641
- References
- 100
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 16 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 23 · 2019: 15 · 2018: 24 · 2017: 26 · 2016: 28 · 2015: 29 · 2014: 31 · 2013: 39 · 2012: 46
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- March of Dimes Foundation
- Larry L. Hillblom Foundation
- National Institutes of Health (U19DK62434)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P50HL56989, P50HL056989)
- National Institute of Diabetes and Digestive and Kidney Diseases (U19 DK-62434, U19DK062434, F32DK071478)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- PPARδ, PPARα, PPARγ, metabolic syndrome, insulin resistance, hypertriglyceridemia, obesity, fatty acid degradation, adipose tissue, skeletal muscle, macrophage inflammation, atherosclerosis, nuclear receptors, weight gain, physical endurance
- MeSH terms
- Animals, Humans, Myocardium, Muscle, Skeletal, Metabolic Syndrome, PPAR delta, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.